Semaglo 0.25 mg Injection contains Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of type 2 diabetes mellitus (T2DM). It is a once-weekly injectable therapy designed to improve glycemic control in adults whose blood sugar is not adequately controlled with diet, exercise, or other antidiabetic medications. Semaglo works by mimicking the action of GLP-1, a natural hormone that regulates blood sugar levels, thereby supporting weight management and reducing cardiovascular risk in diabetic patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

GLP-1 Receptor Agonist / Antidiabetic Agent

Indications

Semaglo 0.25 mg Injection is indicated for:

• Type 2 Diabetes Mellitus (T2DM): As an adjunct to diet and exercise to improve glycemic control in adults

• In combination therapy: Can be used alongside metformin, sulfonylureas, SGLT2 inhibitors, or insulin when additional glycemic control is needed

• Weight management support: Helps reduce body weight in overweight or obese diabetic patients as part of comprehensive management

Pharmacology

Semaglutide is a long-acting GLP-1 receptor agonist that mimics the effects of endogenous GLP-1. Its mechanisms of action include:

• Stimulating insulin secretion from pancreatic β-cells in a glucose-dependent manner

• Suppressing glucagon release, reducing hepatic glucose production

• Slowing gastric emptying, which reduces postprandial glucose spikes

• Promoting satiety, leading to reduced caloric intake and potential weight loss

Semaglutide has a half-life of approximately 1 week, allowing for once-weekly dosing, which improves adherence compared to daily injections.

Dosage and Administration

• Initiation: Start with 0.25 mg once weekly subcutaneously for 4 weeks to reduce gastrointestinal side effects

• Maintenance: After 4 weeks, the dose may be increased to 0.5 mg once weekly, and further up-titrated to 1 mg if additional glycemic control is needed

• Injection sites: Administer subcutaneously in the abdomen, thigh, or upper arm

• Timing: Can be administered at any time of day, with or without food, on the same day each week

Benefits

• Effective reduction in HbA1c levels and fasting plasma glucose

• Supports weight loss in patients with T2DM

• Improves cardiovascular outcomes in high-risk patients

• Convenient once-weekly dosing improves compliance

Contraindications

• Known hypersensitivity to Semaglutide or any component of the formulation

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

• Common: Nausea, vomiting, diarrhea, constipation, abdominal pain

• Less common: Dyspepsia, headache, fatigue

• Rare but serious: Pancreatitis, hypoglycemia (especially when combined with insulin or sulfonylureas), allergic reactions

Precautions and Warnings

• Monitor patients for signs of pancreatitis

• Use caution in patients with renal or hepatic impairment

• Not recommended for type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis

• Advise patients to report persistent gastrointestinal symptoms

Mode of Action

Semaglutide binds to GLP-1 receptors on pancreatic β-cells, enhancing glucose-dependent insulin secretion. It also suppresses glucagon release from α-cells, slows gastric emptying, and increases satiety, resulting in improved glycemic control and potential weight reduction.

Pregnancy and Lactation

• Pregnancy: Use only if clearly needed; no adequate human data available

• Lactation: Safety not established; consider alternative therapy or discontinue breastfeeding

Storage

Store refrigerated at 2–8°C. Do not freeze. Keep the pen in the outer carton to protect from light.